Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck

NEW YORK, September 5, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Novartis AG (NYSE: NVS), InterMune Inc. (NASDAQ: ITMN), Johnson & Johnson (NYSE: JNJ), Amgen Inc. (NASDAQ: AMGN) and Merck & Co., Inc. (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6244-100free.

--
Novartis AG Research Reports
On September 3, 2014, Novartis AG (Novartis) announced that the Company will present its new analysis on Gilenya® at the Joint ACTRIMS-ECTRIMS Meeting in Boston, U.S. on September 10, 2014 through September 13, 2014. The Company informed that its new analysis will add to the growing evidence confirming the importance of redefining treatment goals in multiple sclerosis (MS). Novartis stated that the goal of MS treatment is to have 'no evidence of disease activity' (NEDA), currently defined as no evidence of relapses, MRI lesions and disability progression. The Company further informed that the new data will reinforce the clinical relevance of brain shrinkage (brain volume loss) as well as highlight the benefit of including it as a fourth key measure of MS in the definition of NEDA. In addition, other analyses will reveal that patients treated with Gilenya® (fingolimod) were more likely to achieve NEDA based on assessment of these four key measures, including MS-related brain shrinkage, compared to those on placebo. The full research reports on Novartis are available to download free of charge at:

http://www.analystsreview.com/Sep-05-2014/NVS/report.pdf

--
InterMune Inc. Research Reports
On September 2, 2014, InterMune Inc.'s (InterMune) stock moved up 0.05% to close the trading session at $73.49, creating a new 52-week high of $73.52. Shares in InterMune opened the session at $73.40 and fluctuated between intra-day low of $73.37 and intra-day high of $73.52. Over the past one month, the stock has returned 66.76% outperforming the Nasdaq Composite that returned 5.64% over the same period of time. On August 24, 2014, InterMune announced that it has entered into a definite merger agreement with Roche, under which Roche will fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. The Company's stock has skyrocketed 36.60% from the close on August 22, 2014, last trading day before the acquisition was announced. The full research reports on InterMune are available to download free of charge at:

http://www.analystsreview.com/Sep-05-2014/ITMN/report.pdf

--
Johnson & Johnson Research Reports
On September 2, 2014, Johnson & Johnson (J&J) reported that its subsidiary Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare, released the results from the X-VeRT trial. According to the Company, the results show that once-daily XARELTO® (rivaroxaban) may be an alternative to vitamin K antagonists (VKA) in treating and reducing the risk of blood clots in non-valvular atrial fibrillation (NVAF) patients undergoing elective cardioversion, a procedure to reset the heartbeat back to a regular rhythm. Anne Hermanowski Vosatka, M.D., Ph.D, F.A.C.C., Vice President and Compound Development Team Leader for XARELTO®, Janssen, said, "XARELTO is the most studied and widely prescribed Factor Xa inhibitor in the world today. We remain committed to continuing to advance our understanding of how this medicine can address critical medical needs." J&J added that the results were presented at the ESC Congress 2014 and published in European Heart Journal. The full research reports on Johnson & Johnson are available to download free of charge at:

http://www.analystsreview.com/Sep-05-2014/JNJ/report.pdf

--
Amgen Inc. Research Reports
On September 2, 2014, Amgen Inc. (Amgen) announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for evolocumab to seek approval for the treatment of high cholesterol. The Company informed that evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or 'bad' cholesterol, from the blood. The Company stated that its MAA for evolocumab contains data from approximately 6,800 patients, including more than 4,500 patients with high cholesterol in 10 Phase 3 trials. Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen, said, "Following last week's filing submission to the U.S. FDA, the submission of the Marketing Authorization Application to the European Medicines Agency represents another significant milestone in our global lipid-lowering development program." The full research reports on Amgen are available to download free of charge at:

http://www.analystsreview.com/Sep-05-2014/AMGN/report.pdf

--
Merck & Co., Inc. Research Reports
On September 2, 2014, Merck & Co., Inc. (Merck) announced that it will present the data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the Company's investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, from September 26, 2014 to September 30, 2014. The Company informed that data on pembrolizumab are intended to be presented in five advanced solid tumor types, including the first presentation of data evaluating pembrolizumab for the treatment of gastric and bladder (urothelial tract) cancers. Merck added that three late-breaking abstracts have been accepted for oral presentation. The full research reports on Merck are available to download free of charge at:

http://www.analystsreview.com/Sep-05-2014/MRK/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review